President Donald Trump has generated significant controversy with his dual approach to drug policy during his second term, oscillating between a hardline stance against Mexican cartels and an unexpected trend of granting clemency to convicted drug dealers.
Trump’s recent statements advocating for harsher penalties for drug dealers, particularly those involved in selling fentanyl, have not gone unnoticed.
During a meeting with state governors in February, he proclaimed, “I am ready for it, the death penalty, if you deal drugs,” criticizing the current system for treating drug dealers with only a “slap on the wrist.”
However, his decisions to pardon individuals connected to serious drug offenses have sparked confusion and criticism from various sectors.
Notably, this week he granted clemency to Larry Hoover, 74, a notorious leader of the Chicago-based Gangster Disciples, who was serving multiple life sentences for crimes linked to his role in running a violent drug syndicate.
Jeffrey Singer, a drug policy analyst at the Cato Institute, pointed out the mixed signals from the White House.
“On the one hand you’re threatening even tougher penalties on people who deal in drugs, while on the other hand you’re releasing drug dealers from prisons,” Singer noted, highlighting the discord in Trump’s messaging.
Hoover’s Gangster Disciples have been notorious for their extensive drug trafficking operations, extending across 35 states and generating over $100 million in drug sales annually in Chicago, according to the U.S. Justice Department.
Ron Safer, a former U.S. attorney in Chicago involved in prosecuting Gangster Disciples, expressed his dismay over Trump’s decision to commute Hoover’s sentence, emphasizing the violent nature of the gang’s operations.
“Larry Hoover was the head of perhaps the most pernicious, efficient drug operation in the United States,” Safer stated, underlining the gang’s history of violence and murder associated with maintaining drug territories.
Hoover has been incarcerated since 1973, with significant convictions for murder and drug trafficking charges occurring in the 1990s.
Despite being moved to a state correctional facility in Illinois, Hoover remains behind bars due to a state-level murder conviction, although advocates for his release are hopeful that Illinois officials will follow the federal lead.
A White House spokesman, who spoke on background, indicated that recommendations by advocates for Hoover’s release suggest the time he served has been sufficient.
This latest act of clemency is part of a broader pattern seen during both of Trump’s terms; while advocating for stringent penalties on drug dealing, he has pardoned or commuted sentences of at least 13 individuals convicted of federal drug crimes from 2017 to 2021.
This trend has included high-profile cases, such as that of Ross Ulbricht, the creator of the Silk Road, a dark web marketplace used for drug transactions, who received a commutation from Trump this term.
Critics of the administration have remarked on the double standard in Trump’s drug policy approach.
Kassandra Frederique, head of the Drug Policy Alliance, summarized these tensions well.
She noted that while Trump’s clemency decisions provide crucial opportunities for those affected by the drug war, they stand in stark contrast to his overall tough-on-crime rhetoric and ongoing dismantling of public health services related to drug addiction.
Frederique expressed cautious praise for the individual clemencies while questioning the consistent inconsistency in Trump’s drug war policy.
Additionally, Trump’s earlier administration faced pressure to drop prosecutions against influential figures linked to drug trafficking, such as General Salvador Cienfuegos Zepeda, a retired Mexican military official, highlighting a complex relationship with international drug enforcement.
Despite the contradictions presented by Trump’s actions, some interpretations suggest a transactional nature to his pardons, influenced by powerful individuals and advocacy rather than a coherent ideology.
Singer remarked that Trump’s clemency decisions appear transactional, often linked to political promises rather than a clear ideological thread, citing Trump’s prior assurance at the Libertarian Party convention about pardoning Ulbricht.
As he seeks another term in office, Trump has openly linked his drug policy plans to his presidential campaign, vowing to commute Ulbricht’s sentence on day one of his potential new administration.
The influence of celebrity advocates in drug clemency also plays an important role, with figures like Ye (formerly Kanye West) publicly expressing gratitude to Trump for Hoover’s release.
Ye described Trump as a “devoted enduring president” in a recent post, demonstrating the intersection of celebrity culture with political actions.
Moreover, Trump’s actions mirror a larger trend in U.S. politics, where exiting presidents, such as Joe Biden, have also taken steps toward addressing disparities in drug-related sentencing.
Biden’s series of pardons at the end of his term reflected a shift in approach, emphasizing a desire to correct past injustices in the criminal justice system, particularly regarding drug offenses.
Experts note the difficulty in discerning a cohesive rationale behind Trump’s use of clemency, leaving observers to grapple with the fundamental contradictions in his drug policy.
As Trump navigates his 2024 campaign, the public will likely continue to witness the complexities and contradictions of his stance on drug policy—a juxtaposition of tough rhetoric against leniency for select individuals involved in drug trafficking.
image source from：https://www.npr.org/2025/05/31/nx-s1-5415939/trump-pardons-drug-kingpins-even-as-he-escalates-the-u-s-drug-war
